key: cord-0823105-0en81s5w authors: Ralli, Massimo; Arcangeli, Andrea; Soave, Paolo Maurizio; Voglino, Cristina; De-Giorgio, Fabio title: SARS-CoV-2 seroprevalence in the Vatican City State date: 2021-02-04 journal: Eur J Intern Med DOI: 10.1016/j.ejim.2021.01.029 sha: 2ef28c8b371c1e2dfc6cead942a3394a7d937ea9 doc_id: 823105 cord_uid: 0en81s5w nan SARS-CoV-2; COVID-19; Vatican City State; Seroprevalence. The ongoing Coronavirus Disease 19 (COVID-19) pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has affected so far 218 countries with over 94 million cases, about 2 million deaths and over 67 million recovered (1), with dramatic effects on communities and healthcare systems (2) . The beginning of mass vaccination campaigns in late 2020 in the USA and the UK, and from early 2021 in other countries, will help controlling the infection spread and limiting its consequences, also providing indirect protection to non-vaccinated individuals through the mechanism of "herd immunity" (3) (4) (5) . In the first eleven months of the pandemic, 42 COVID-19 cases were tracked in the Vatican City State, an enclave of the City of Rome, Italy, with about 800 residents and 5,000 employees. During this time, the Directorate of Health and Hygiene of the Governorate of the Vatican City State, the entity deputed to provide internal healthcare assistance to residents, employees, retirees and their families, underwent several changes in its ordinary activities and introduced multiple prevention and control measures to limit SARS-CoV-2 spread within the State (6). A few months after the first wave of the pandemic, the Directorate of Health and Hygiene started a serological evaluation of anti-SARS-CoV-2 antibodies in residents and employees of the Vatican City State, regardless of symptoms or contacts with positive cases. The analysis begun on June 8, 2020 and, as of January 4, 2021, included 1472 subjects. One serological test per subject was considered for this report; repeated tests over time on the same subjects were not included. Serological tests were performed on peripheral blood using the SARS-CoV-2 Total Assay, Atellica IM COV2T method (Siemens Healthineers AG, Germany), a fully automated 1-step sandwich immunoassay using acridinium ester chemiluminescence technology, designed to detect the spike protein receptor-binding domain on the surface of SARS-CoV-2. This method has shown a high sensitivity (97.48%) and specificity (99.80%). A test was considered positive when had an index equal or higher than 1 (measuring interval: 0.05-10.00). Data analysis was performed using Prism This study has several limits. The main is that our analysis only focused on the cumulative seroprevalence of anti-SARS-CoV-2 antibodies without dividing between Immunoglobulin M (IgM) and Immunoglobulin G (IgG). In addition, the correlation of the antibody index with the result of a nasopharyngeal RT-PCR test was not available. Last, this methodology had a measuring interval between 0.05 and 10; the value of cases with an index < 0.05 and > 10 were considered as 0.05 and 10, respectively, in the evaluation of means and standard deviations and errors. Future epidemiological studies including a larger percentage of the target population may be necessary to evaluate the changes in seroprevalence over time. Furthermore, additional analyses will be important to evaluate the effects of the COVID-19 vaccine. At this regard, the introduction of a mass vaccination campaign in the Vatican City State, starting on January 13, 2021 and aiming to vaccinate at least 70% of the total population assisted by the healthcare services of the Vatican City State over 18 years of age, will be of utmost importance in the control of infection spread. It will also be extraordinarily important given the reported low seroprevalence of SARS-CoV-2, that exposes this population to higher risk for contagion if unprotected. The authors declare they have no conflict of interest. None COVID-19: The Waterloo of governments, healthcare systems, and large health organizations COVID-19 herd immunity: where are we? Immunological considerations for COVID-19 vaccine strategies European Federation of Internal Medicine AWG. ADVICE for a healthier life: Adult Vaccination Campaign in Europe The Vatican City State Internal Healthcare System Response to COVID-19 Pandemic: Prevention and Control Strategies. Appl Health Econ Health Policy Seroprevalence of SARS-CoV-2 antibodies in over 6000 healthcare workers in Spain Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris The average antibody index was 6.43 for positive subjects and 0.44 for negative subjects. Dotted line indicates threshold for positive antibody index. B) Comparison of the total COVID-19 cases both at nasopharyngeal swab test (PCR) and serological test (Serology) in the Vatican City State from The authors wish to thank all the personnel of the Directorate of Health and Hygiene of the Vatican City State, including general and specialty medical doctors, nurses, physiotherapists, dental, radiologic and laboratory technicians, operators, and administrative employees, that worked hard during the pandemic to ensure an uninterrupted and highly professional service.